pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-2-89-94pulmo-178Research ArticleЛЕКЦИИLECTIONSПринципы выбора препаратов для лечения хронической обструктивной болезни легких согласно новым международным клиническим рекомендациямPrinciples of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelinesТатарскийА. Р.TatarskyA. R.

д. м. н., проф. кафедры госпитальной терапии педиатрического факультета 

117513, Москва, ул. Островитянова, 1, стр. 9. Тел.: (495) 465-52-64.

ГБОУ ВПО "РНИМУ им. Н.И.Пирогова" Минздрава РоссииRussian Federation201328042013028994Copyright © Татарский А.Р., 20132013Татарский А.Р.Tatarsky A.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/178

Принципы выбора препаратов для лечения хронической обструктивной болезни легких согласно новым международным клиническим рекомендациям.

Principles of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelines.

хроническая обструктивная болезнь легкихGOLD 2011терапияchronic obstructive pulmonary diseaseGOLD 2011therapyReferencesГлобальная инициатива по хронической обструктивной болезни легких. Пересмотр 2003 г. Пер. с англ. М.: Издательство "Атмосфера"; 2003.Глобальная инициатива по хронической обструктивной болезни легких. Пересмотр 2003 г. Пер. с англ. М.: Издательство "Атмосфера"; 2003.Global initiative for chronic obstructive lung disease (GOLD); 2006. www.cgsmedicare.comGlobal initiative for chronic obstructive lung disease (GOLD); 2006. www.cgsmedicare.comGlobal initiative for chronic obstructive lung disease (GOLD); 2011. www.cuidadosintensivos.netGlobal initiative for chronic obstructive lung disease (GOLD); 2011. www.cuidadosintensivos.netGlobal initiative for chronic obstructive lung disease (GOLD); 2012. www.member.ghc.orgGlobal initiative for chronic obstructive lung disease (GOLD); 2012. www.member.ghc.orgAgustí A., Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterization. Eur. Respir. J. 2011; 38: 749–751. DOI: 10.1183/09031936.00062211.Agustí A., Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterization. Eur. Respir. J. 2011; 38: 749–751. DOI: 10.1183/09031936.00062211.Chetta A., Zanini A., Foresi A. et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 751–757.Chetta A., Zanini A., Foresi A. et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 751–757.Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.Lundbäck B., Ronmark E., Lindberg A. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.Lundbäck B., Ronmark E., Lindberg A. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A. The burden of asthma in Australia. Med. J. Aust. 2001; 175 (3): 141–145.Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A. The burden of asthma in Australia. Med. J. Aust. 2001; 175 (3): 141–145.Авдеев С.Н. Антибактериальная терапия при обострении хроничеческой обструктивной болезни легких. Пульмонология 2010; 2: 96–106.Авдеев С.Н. Антибактериальная терапия при обострении хроничеческой обструктивной болезни легких. Пульмонология 2010; 2: 96–106.Cazzola W., MacNee F.J. Martinez. Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.Cazzola W., MacNee F.J. Martinez. Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.Mahler D.A. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.Mahler D.A. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.Vestbo J. New thinking and COPD. Ugeskr Laeger. 2003; 165 (45): 4319.Vestbo J. New thinking and COPD. Ugeskr Laeger. 2003; 165 (45): 4319.Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur. Respir. J. 2004; 24 (2): 206–210.Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur. Respir. J. 2004; 24 (2): 206–210.Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.

The authors declare that there are no conflicts of interest present.